Language: en /
da
Contact
Search:
Core Competences
Pipeline
Business Development
Investor
Join Us
About Us
Cancer
Biodefence
Infectious Diseases
Investor
News
Annual Report 2011
Media Clippings
Share Information
Financials
Calendar
Presentations
General Meetings
Investor Services
Contact
Prostate Cancer Symposium
27 April 2011
Click here
Recent articles
Training immune system to fight cancer comes of age
We're Letting Our Bioterrorism Defenses Down
Reuters article on PROSTVAC
Taking Stock of the Biodefense Boom
Reinventing Project BioShield
U.S. House Panel Endorses Biodefense Legislation
Expert warns that improvement needed on U.S. biodefense
Prostate Cancer Symposium
Why We Still Need Smallpox
Ipilimumab Approval Highlights Active Immunotherapy Renaissance
Using a Cancer Vaccine to Provide Hope
To Partner, or Not to Partner: That is the Question
Bioterror Fears Prompt U.S. to Keep Its Smallpox Cache
A Deadly Virus We May Still Need
Medicare Panel Backs Prostate Drug
Senators Ask Why Medicare Is Reviewing Provenge
Counter-Bioterrorism Reform Plan Looks Promising, Experts Say
Feds to Devote New Funds to Fight Flu, Bioterror
Gains in Bioscience Cause Terror Fears
Dendreon's $93,000 Cancer Drug Price Must Be Paid by U.S., Doctors Say
Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?
Smallpox vaccine may offer protection against HIV infection
The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019
First Smallpox Vaccine for Special Populations Delivered Under Project BioShield
Next-generation smallpox vaccine being stockpiled
White House Aims to Boost U.S. Biosecurity
SLU Studies New Smallpox Vaccine
U.S. Biodefense Spending to Increase
Aetna Confirms It Will Cover Provenge
New prostate cancer vaccine
Vaccine Injection Targeted in Building a Better ‘Bull’s-Eye’ to Fight Prostate Cancer
U.S. stockpile receives smallpox vaccine
